BREYANZI® CAR T Cell Therapy Monitoring and Activity Updates Approved in Canada

About this update from Bristol-myers Squibb Company

Canadian product monograph changes may provide patients greater flexibility following treatment MONTREAL, June 17, 2026 /CNW/ - Bristol Myers Squibb Canada (BMS) is pleased to announce an update to the Canadian product monograph for BREYANZI® (lisocabtagene maraleucel), a CD19-directed chimeric antigen receptor T (CAR T) cell therapy, reducing the duration of certain post-treatment monitoring and activity restrictions for eligible patients following infusion. The updated guidance includes a reduction in the recommended duration for patients to remain in close proximity to a specialized treatment centre from 28 days to 14 days following infusion, as well as a reduction in driving restrictions from eight weeks to four weeks. Clinical decisions regarding patient discharge and ongoing monitoring will continue to be determined by the treating healthcare professional based on individual patient needs. The product monograph updates are supported by a growing body of evidence demonstrating that the risk of treatment-related adverse events decreases significantly after the first 14 days following infusion and are informed by safety data from seven clinical trials involving 691 patients, as well as real-world registry data from 877 patients treated with BREYANZI. "Clinical experience with BREYANZI has continued to expand in both clinical trial and real-world settings, contributing to a deeper understanding of how patients with relapsed or refractory large B-cell lymphomas can be appropriately monitored following treatment," said Dr. Michael Kennah, a hematologist specializing in cellular therapies at The Ottawa Hospital. "CAR T cell therapy has transformed outcomes for many patients facing these aggressive lymphomas, and these updates reflect the growing body of evidence and clinical experience informing post-treatment patient management. The revised timelines may support greater flexibility during the post-treatment period and help lessen the logistical and emotional burden associated with care, while maintaining individualized oversight and patient safety." The revised monitoring requirements create greater flexibility in follow-up care alleviating capacity pressures at specialized CAR T treatment centres by enabling appropriate patients to transition back to community-based care sooner. "For patients and their families or caregivers...

View stock analysis, news, and events for Bristol-myers Squibb Company